This is to inform you that pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, the Board of Directors of the Company in its meeting held on Monday, 02nd February, 2026 at 3:00 ....
Awaiting price reaction for this filing.
The Board of MPS Pharmaa (formerly Advik Laboratories) approved standalone unaudited financial results for Q3 FY26 and nine months ended 31 December 2025. The company reported zero revenue from operations for the period, with total income of just Rs. 4.38 lakh in Q3 (vs Rs. 4.77 lakh YoY), entirely from other income. Net loss for Q3 stood at Rs. 22.03 lakh (vs Rs. 17.46 lakh loss YoY), while nine-month loss widened to Rs. 66.06 lakh. The auditor issued a Qualified Conclusion flagging investments of Rs. 53.80 lakh not fair-valued under Ind AS and stalled capital work-in-progress of Rs. 2.49 crore requiring impairment review. The auditor also highlighted an Emphasis of Matter on the complete absence of operating revenue and non-disclosure of the impact of the New Labour Code on gratuity provisions. Other equity is deeply negative at Rs. (1,803) lakh against paid-up capital of Rs. 1,911 lakh.
This is a deeply negative filing for shareholders. The company has no operating business, its drug manufacturing licence renewal is pending with FDA Panchkula, and it has not paid BSE annual listing fees since FY22 (shares trade on trade-for-trade basis). Accumulated losses have wiped out shareholder equity, signalling serious going-concern risks. Expect continued pressure on the stock and heightened chance of further trading restrictions.